leqvio solution
novartis pharmaceuticals canada inc - inclisiran (inclisiran sodium) - solution - 284mg - inclisiran (inclisiran sodium) 284mg
leqvio 284 mg
novartis israel ltd - inclisiran as sodium - solution for injection - inclisiran as sodium 189 mg/ml - inclisiran - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:• in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl c goals with the maximum tolerated dose of a statin, or• alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.
pettit marine paint vivid antifouling paint
resene paints (australia) limited - copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; copper present as cuprous thiocyanate; zinc pyrithione; zinc pyrithione; zinc pyrithione; zinc pyrithione; zinc pyrithione - paint - copper present as cuprous thiocyanate cyanide active 226.0 g/l; copper present as cuprous thiocyanate cyanide active 228.0 g/l; copper present as cuprous thiocyanate cyanide active 247.0 g/l; copper present as cuprous thiocyanate cyanide active 247.0 g/l; copper present as cuprous thiocyanate cyanide active 251.0 g/l; zinc pyrithione mineral-zinc active 48.5 g/l; zinc pyrithione mineral-zinc active 49.5 g/l; zinc pyrithione mineral-zinc active 44.6 g/l; zinc pyrithione mineral-zinc active 48.5 g/l; zinc pyrithione mineral-zinc active 43.7 g/l - antifouling
incruse ellipta
glaxosmithkline nz limited - umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg; - powder for inhalation - 62.5 mcg - active: umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg excipient: lactose monohydrate magnesium stearate - incruse ellipta is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).
increlex solution
ipsen biopharmaceuticals canada inc - mecasermin - solution - 40mg - mecasermin 40mg - somatotropin agonists*
lactisol nucleus z
dsm nutritional products new zealand limited - oral nutritional compound; zinc oxide - oral nutritional compound 0 g/kg; zinc oxide 450 g/kg - antidote
nucleus custom sound suite - cochlear implant system evaluation application software
cochlear ltd - 58734 - cochlear implant system evaluation application software - cochlear nucleus custom sound suite is a nucleus cochlear implant programming software that determines the way sounds are processed and presented to the nerve through its settings. using custom sound suite, the required electrode stimulation levels are measured for each cochlear implant recipient and set to appropriate levels. cochlear nucleus custom sound suite includes two pieces of software: custom sound and custom sound ep. software or interface between the computer and the sound processor to enable programming of the cochlear implant system.
fuzeon
roche products (nz) ltd - enfuvirtide 108mg (includes overage 20%) - injection with diluent - 90 mg/ml - active: enfuvirtide 108mg (includes overage 20%) excipient: hydrochloric acid mannitol sodium carbonate sodium hydroxide water for injection - fuzeon (enfuvirtide) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral experienced patients with treatment failure due to intolerance to previous antiretroviral agents or with evidence of hiv-1 replication despite ongoing therapy. evidence to support this indication is based on surrogate endpoints (change in viral load and cd4 count) in controlled studies following 48 weeks of treatment (see clinical trials).
incivo
janssen-cilag pty ltd - telaprevir -
clopidogrel nucleus
nucleus ehf. - clopidogrel besilate - film coated tablet - 75 base milligrams